Jacobio Pharma, Oceanpine Capital and Partner Acquire Majority of Jacoray, Fuelling Early‑Stage Cardio‑Oncology R&D
Jacobio Pharma Ltd. (HKG: 1167) announced today that its subsidiary Beijing Jacobio Pharmaceuticals Co., Ltd....
Walvax Biotechnology & Pharmaniaga Lifescience Forge Malaysia Partnership for PCV‑13 Production and Distribution
Walvax Biotechnology Co., Ltd. and Pharmaniaga Lifescience Sdn. Bhd. (wholly‑owned by Pharmaniaga Berhad) today announced a...
Shandong Buchang’s Luzhou Unit Moves to Secure Exclusive Distribution of Epo‑IgG Fusion in Vietnam
Shandong Buchang Pharmaceuticals Co., Ltd. (SHA: 603858) announced today that its subsidiary Luzhou Buchang will enter...
AnkeBio and PersonGen Ink Capital‑Increase Deal, Secure Exclusive Greater‑China Agency for PA3‑17 CAR‑T Therapy
Anhui Anke Biotechnology (Group) Co., Ltd. and PersonGen BioTherapeutics (Suzhou) Co., Ltd. (PersonGen) announced today...
Chongqing Precision Biotech Wins NMPA Approval for pCAR‑19B – China’s First Humanised CD19 CAR‑T Therapy for Pediatric B‑ALL
Chongqing Precision Biotech Co., Ltd. announced that its pCAR‑19B cell‑based product has received National Medical...
Laekna and Qilu Pharma Sign Exclusive China License for AKT Inhibitor LAE002 (Afuresertib)
Sino-US biotech Laekna Therapeutics (HKG: 2105) and Qilu Pharmaceutical Co., Ltd. announced today an exclusive...
NMPA Grants Marketing Authorisation to Hefei Amvite’s Memantine Hydrochloride ODT for Alzheimer’s Disease
The National Medical Products Administration (NMPA) has approved Memantine Hydrochloride Orally Disintegrating Tablets (ODT) produced...
Shanghai Henlius Biotech Secures UK MHRA Approval for Denosumab Biosimilars BILDYOS & BILPREVDA
Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that the United Kingdom’s Medicines and Healthcare Products...
Novo Nordisk Announces Major China Business Restructuring Effective Jan 1 2026
Novo Nordisk A/S (NYSE: NVO) released an internal memorandum outlining a sweeping re‑organization of its...
Huadong Medicine Files NDA for Roflumilast Cream (ZORYVE) – First PDE‑4 Topical for Atopic Dermatitis in Greater China
Huadong Medicine Co., Ltd. (SHE: 000963) announced that China’s National Medical Products Administration (NMPA) has...
Gan & Lee Transfers MedTech Control to Hillhouse Investment, Accelerating Drug Delivery Innovation
Gan & Lee Pharmaceuticals (SHA: 603087) announced today that it has transferred its controlling stake...
Sanyou Biopharmaceuticals & Yugong Biotech Forge Strategic Enzyme Development Alliance
Sanyou Biopharmaceuticals Co., Ltd. and Yugong Biotech Co., Ltd. today signed a strategic cooperation agreement...
Grand Pharmaceutical & Glenmark Specialty Secure China NMPA Approval for Ryaltris Nasal Spray
Grand Pharmaceutical Group Limited (HKG: 0512) together with Glenmark Specialty S.A. announced that the Ryaltris...
Lepu Biopharma Secures FDA IND Clearance for CDH17‑Targeted ADC MRG007
Lepu Biopharma Co., Ltd. (HKG: 2157) announced that the U.S. Food and Drug Administration (FDA)...
Novartis Wins FDA Approval for Remibrutinib Tablets – First BTK Inhibitor for Chronic Spontaneous Urticaria
Novartis AG (NYSE: NVS) announced that the U.S. Food and Drug Administration (FDA) has granted...
Lyell Immunopharma Secures Global Rights to LYL273 CAR‑T Therapy – Major Step Toward mCRC Treatment
Lyell Immunopharma, Inc. (NASDAQ: LYEL) announced the execution of a definitive licensing agreement with Innovative...
DualityBio Secures FDA Fast‑Track Designation for EGFR/HER3 Bispecific ADC AVZO‑1418
Duality Biotherapeutics, Inc. (DualityBio, HKG: 9606) announced that its co‑developed EGFR/HER3 bispecific antibody‑drug conjugate (ADC),...
Mabwell Partners with Ping An Health to Launch Integrated Bone‑Health & Autoimmune Care Platform
Mabwell Bioscience (SHA: 688062) disclosed a strategic, deep‑level collaboration with Ping An Healthcare and Technology...
Roche Announces Positive Phase III Results for Fenebrutinib in Relapsing & Primary‑Progressive Multiple Sclerosis
Roche Holding AG (SWX: ROG, OTCMKTS: RHHBY) reported that both pivotal Phase III trials of its...
Simcere Launches Phase II Trial of T‑Reg‑Selective IL‑2 Fusion (SIM0278) for Moderate‑to‑Severe Atopic Dermatitis in China
Simcere Pharmaceutical Group Ltd. (HKG: 2096) announced that the Phase II clinical study of its proprietary...